NA Travel Vaccine Market - Industry Trends and Forecast to 2035

Description

List of Tables

North America travel vaccine market is expected to reach USD 3,999,023.57 thousand by 2032 from USD 1,743,097.85 thousand in 2023, growing at a substantial CAGR of 9.8% in the forecast period of 2024 to 2032.

Market Segmentation:

By Composition (Combination Vaccines and Mono Vaccines), Type (Inactivated Vaccines, Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, DNA Vaccines, and Viral Vector Vaccines), Category (Recommended Vaccine, Routine Vaccine and Required Vaccine), Disease (Typhoid, Hepatitis, Cholera, Varicella, Influenza, Japanese Encephalitis, Meningococcal Meningitis, Yellow Fever, Rabies, DPT, Measles and Mumps, Tick-Borne Encephalitis, Malaria, Covid-19, Polio and Others), Route of Administration (Injectable and Oral), Gender (Male and Female), Patient Type (Adult, Pediatric and Geriatric), Age Group (20-50 Years, Less than 20 Years and Above 50 Years), Distribution Channel (B2B and B2C), Countries (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2032

Some of the major factors contributing to the growth of the North America travel vaccines market are:

Driver
Rising incidence of infectious diseases
Restraint
High cost of travel vaccines
Opportunity
Advancements in vaccine technology

Market Players

Some major companies dealing in the North America travel vaccines market are:

GSK plc.
Bavarian Nordic
Pfizer Inc.
Abbott
CSL
AstraZeneca
Sanofi
Merck & Co., Inc.
Valneva SE
Johnson & Johnson Services Inc.
Dynavax Technologies.

1 INTRODUCTION 49

1.1 OBJECTIVES OF THE STUDY 49
1.2 MARKET DEFINITION 49
1.3 OVERVIEW OF NORTH AMERICA TRAVEL VACCINES MARKET 49
1.4 LIMITATIONS 51
1.5 MARKETS COVERED 51

2 MARKET SEGMENTATION 55

2.1 MARKETS COVERED 55
2.2 GEOGRAPHICAL SCOPE 56
2.3 YEARS CONSIDERED FOR THE STUDY 57
2.4 CURRENCY AND PRICING 57
2.5 DBMR TRIPOD DATA VALIDATION MODEL 58
2.6 MULTIVARIATE MODELLING 61
2.7 PRODUCT TYPE LIFELINE CURVE 61
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
2.9 DBMR MARKET POSITION GRID 63
2.10 MARKET APPLICATION COVERAGE GRID 64
2.11 VENDOR SHARE ANALYSIS 65
2.12 SECONDARY SOURCES 66
2.13 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 70

4.1 PESTEL ANALYSIS 71
4.2 PORTER'S FIVE FORCES 72
4.3 PIPELINE ANALYSIS 73

5 MARKET OVERVIEW 77

5.1 DRIVERS 79
- 5.1.1 RISING INCIDENCE OF INFECTIOUS DISEASES 79
- 5.1.2 INCREASING TRAVEL AND TOURISM 81
- 5.1.3 GOVERNMENT REGULATIONS AND RECOMMENDATIONS REGARDING VACCINATION 82
- 5.1.4 EXPANSION OF TRAVEL MEDICINE CLINICS 82
5.2 RESTRAINTS 83
- 5.2.1 HIGH COST OF TRAVEL VACCINES 83
- 5.2.2 REGULATORY HURDLES FOR APPROVAL 84
5.3 OPPORTUNITIES 84
- 5.3.1 ADVANCEMENTS IN VACCINE TECHNOLOGY 84
- 5.3.2 GROWING AWARENESS REGARDING VACCINES 85
- 5.3.3 INTEGRATION OF DIGITAL HEALTH SOLUTIONS 85
5.4 CHALLENGES 86
- 5.4.1 COLD CHAIN REQUIREMENTS FOR STORAGE 86
- 5.4.2 VACCINE HESITANCY AND MISINFORMATION 87

6 NORTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION 88

6.1 OVERVIEW 89
6.2 COMBINATION VACCINES 92
6.3 MONO VACCINES 92

7 NORTH AMERICA TRAVEL VACCINE MARKET, BY TYPE 93

7.1 OVERVIEW 94
7.2 INACTIVATED VACCINES 97
- 7.2.1 HEPATITIS A 98
- 7.2.2 INFLUENZA 98
- 7.2.3 RABIES 98
- 7.2.4 TICK-BORNE ENCEPHALITIS 98
- 7.2.5 JAPANESE ENCEPHALITIS 98
- 7.2.6 POLIO 99
7.3 SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES 99
- 7.3.1 HEPATITIS B 100
- 7.3.2 MENINGOCOCCAL 100
- 7.3.3 MALARIA 100
- 7.3.4 COVID-19 100
7.4 LIVE-ATTENUATED VACCINES 101
- 7.4.1 TYPHOID 102
- 7.4.2 CHOLERA 102
- 7.4.3 YELLOW FEVER 102
- 7.4.4 MEASLES 102
- 7.4.5 MUMPS 103
- 7.4.6 RUBELLA 103
- 7.4.7 VARICELLA 103
- 7.4.8 OTHERS 103
7.5 TOXOID VACCINES 103
- 7.5.1 DIPHTHERIA 104
- 7.5.2 TETANUS 104
7.6 DNA VACCINES 104
7.7 VIRAL VECTOR VACCINES 105

8 NORTH AMERICA TRAVEL VACCINE MARKET, BY CATEGORY 106

8.1 OVERVIEW 107
8.2 RECOMMENDED VACCINE 110
- 8.2.1 TYPHOID FEVER VACCINES 111
- 8.2.2 HEPATITIS A 111
- 8.2.3 CHOLERA 111
- 8.2.4 RABIES 111
- 8.2.5 TICK-BORNE ENCEPHALITIS 111
- 8.2.6 JAPANESE ENCEPHALITIS 111
- 8.2.7 MALARIA 111
- 8.2.8 OTHERS 111
8.3 ROUTINE VACCINE 112
- 8.3.1 HEPATITIS B 113
- 8.3.2 INFLUENZA VACCINES 113
- 8.3.3 PNEUMOCOCCAL 113
- 8.3.4 DIPHTHERIA 113
- 8.3.5 TETANUS 113
- 8.3.6 MEASLES 113
- 8.3.7 MUMPS 113
- 8.3.8 RUBELLA 113
- 8.3.9 PERTUSSIS 113
- 8.3.10 OTHERS 114
8.4 REQUIRED VACCINE 114
- 8.4.1 YELLOW FEVER 115
- 8.4.2 MENINGOCOCCAL 115
- 8.4.3 POLIO VACCINES 115

9 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISEASE 116

9.1 OVERVIEW 117
9.2 TYPHOID 121
9.3 HEPATITIS 121
- 9.3.1 HEPATITIS A 122
- 9.3.2 HEPATITIS B 122
9.4 CHOLERA 122
9.5 VARICELLA 123
9.6 INFLUENZA 123
9.7 JAPANESE ENCEPHALITIS 124
9.8 MENINGOCOCCAL MENINGITIS 124
9.9 YELLOW FEVER 125
9.10 RABIES 125
9.11 DPT 126
9.12 MEASLES AND MUMPS 126
9.13 TICK-BORNE ENCEPHALITIS 127
9.14 MALARIA 127
9.15 COVID-19 128
9.16 POLIO 128
9.17 OTHERS 129

10 NORTH AMERICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION 130

10.1 OVERVIEW 131
10.2 INJECTABLE 134
- 10.2.1 INTRAMUSCULAR 135
- 10.2.2 SUBCUTANEOUS 135
- 10.2.3 OTHERS 135
10.3 ORAL 135

11 NORTH AMERICA TRAVEL VACCINE MARKET, BY GENDER 136

11.1 OVERVIEW 137
11.2 MALE 140
11.3 FEMALE 140

12 NORTH AMERICA TRAVEL VACCINE MARKET, BY PATIENT TYPE 141

12.1 OVERVIEW 142
12.2 ADULT 145
12.3 PEDIATRIC 145
12.4 GERIATRIC 146

13 NORTH AMERICA TRAVEL VACCINE MARKET, BY AGE GROUP 147

13.1 OVERVIEW 148
13.2 20-50 YEARS 151
13.3 LESS THAN 20 YEARS 152
13.4 ABOVE 50 YEARS 153

14 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL 154

14.1 OVERVIEW 155
14.2 B2B 158
14.3 B2C 158

15 NORTH AMERICA TRAVEL VACCINE MARKET, BY REGION 159

15.1 NORTH AMERICA 162
- 15.1.1 U.S. 170
- 15.1.2 CANADA 177
- 15.1.3 MEXICO 185

16 NORTH AMERICA TRAVEL VACCINE MARKET: COMPANY LANDSCAPE 192

16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 192

17 SWOT ANALYSIS 193

18 COMPANY PROFILE 194

18.1 PFIZER INC. 194
- 18.1.1 COMPANY SNAPSHOT 194
- 18.1.2 REVENUE ANALYSIS 194
- 18.1.3 COMPANY SHARE ANALYSIS 195
- 18.1.4 PRODUCT PORTFOLIO 195
- 18.1.5 RECENT DEVELOPMENT 196
18.2 SANOFI 197
- 18.2.1 COMPANY SNAPSHOT 197
- 18.2.2 REVENUE ANALYSIS 197
- 18.2.3 COMPANY SHARE ANALYSIS 198
- 18.2.4 PRODUCT PORTFOLIO 198
- 18.2.5 RECENT DEVELOPMENT 202
18.3 JOHNSON & JOHNSON SERVICES INC. 203
- 18.3.1 COMPANY SNAPSHOT 203
- 18.3.2 REVENUE ANALYSIS 203
- 18.3.3 COMPANY SHARE ANALYSIS 204
- 18.3.4 PRODUCT PORTFOLIO 204
- 18.3.5 RECENT DEVELOPMENTS 205
18.4 GSK PLC. 206
- 18.4.1 COMPANY SNAPSHOT 206
- 18.4.2 REVENUE ANALYSIS 206
- 18.4.3 COMPANY SHARE ANALYSIS 207
- 18.4.4 PRODUCT PORTFOLIO 207
- 18.4.5 RECENT DEVELOPMENT 212
18.5 MERCK & CO., INC. 214
- 18.5.1 COMPANY SNAPSHOT 214
- 18.5.2 REVENUE ANALYSIS 214
- 18.5.3 COMPANY SHARE ANALYSIS 215
- 18.5.4 PRODUCT PORTFOLIO 215
- 18.5.5 RECENT DEVELOPMENT 217
18.6 ABBOTT 218
- 18.6.1 COMPANY SNAPSHOT 218
- 18.6.2 REVENUE ANALYSIS 218
- 18.6.3 PRODUCT PORTFOLIO 219
- 18.6.4 RECENT DEVELOPMENT 220
18.7 ASTRAZENECA 221
- 18.7.1 COMPANY SNAPSHOT 221
- 18.7.2 REVENUE ANALYSIS 221
- 18.7.3 PRODUCT PORTFOLIO 222
- 18.7.4 RECENT DEVELOPMENT 222
18.8 BAVARIAN NORDIC 224
- 18.8.1 COMPANY SNAPSHOT 224
- 18.8.2 REVENUE ANALYSIS 224
- 18.8.3 PRODUCT PORTFOLIO 225
- 18.8.4 RECENT DEVELOPMENT 225
18.9 CSL 227
- 18.9.1 COMPANY SNAPSHOT 227
- 18.9.2 REVENUE ANALYSIS 227
- 18.9.3 PRODUCT PORTFOLIO 228
- 18.9.4 RECENT DEVELOPMENT 229
18.10 DYNAVAX TECHNOLOGIES. 230
- 18.10.1 COMPANY SNAPSHOT 230
- 18.10.2 REVENUE ANALYSIS 230
- 18.10.3 PRODUCT PORTFOLIO 231
- 18.10.4 RECENT DEVELOPMENTS 231
18.11 VALNEVA SE 232
- 18.11.1 COMPANY SNAPSHOT 232
- 18.11.2 REVENUE ANALYSIS 232
- 18.11.3 PRODUCT PORTFOLIO 233
- 18.11.4 RECENT DEVELOPMENT 233

19 QUESTIONNAIRE 234

20 RELATED REPORTS 238

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS OF TRAVEL VACCINES MARKET 43
TABLE 2 VACCINES RECOMMENDATION FOR INTERNATIONAL TRAVELERS 49
TABLE 3 NORTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 61
TABLE 4 NORTH AMERICA COMBINATION VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 62
TABLE 5 NORTH AMERICA MONO VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 62
TABLE 6 NORTH AMERICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 66
TABLE 7 NORTH AMERICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 67
TABLE 8 NORTH AMERICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 68
TABLE 9 NORTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 69
TABLE 10 NORTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 70
TABLE 11 NORTH AMERICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 71
TABLE 12 NORTH AMERICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 72
TABLE 13 NORTH AMERICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 73
TABLE 14 NORTH AMERICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 74
TABLE 15 NORTH AMERICA DNA VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 74
TABLE 16 NORTH AMERICA VIRAL VECTOR VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 75
TABLE 17 NORTH AMERICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 79
TABLE 18 NORTH AMERICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 80
TABLE 19 NORTH AMERICA RECOMMENDED VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 80
TABLE 20 NORTH AMERICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 82
TABLE 21 NORTH AMERICA ROUTINE VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 82
TABLE 22 NORTH AMERICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 84
TABLE 23 NORTH AMERICA REQUIRED VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 84
TABLE 24 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 90
TABLE 25 NORTH AMERICA TYPHOID IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 91
TABLE 26 NORTH AMERICA HEPATITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 91
TABLE 27 NORTH AMERICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 92
TABLE 28 NORTH AMERICA CHOLERA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 92
TABLE 29 NORTH AMERICA VARICELLA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 93
TABLE 30 NORTH AMERICA INFLUENZA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 93
TABLE 31 NORTH AMERICA JAPANESE ENCEPHALITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 94
TABLE 32 NORTH AMERICA MENINGOCOCCAL MENINGITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 94
TABLE 33 NORTH AMERICA YELLOW FEVER IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 95
TABLE 34 NORTH AMERICA RABIES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 95
TABLE 35 NORTH AMERICA DPT IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 96
TABLE 36 NORTH AMERICA MEASLES AND MUMPS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 96
TABLE 37 NORTH AMERICA TICK-BORNE ENCEPHALITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 97
TABLE 38 NORTH AMERICA MALARIA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 97
TABLE 39 NORTH AMERICA COVID-19 IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 98
TABLE 40 NORTH AMERICA POLIO IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 98
TABLE 41 NORTH AMERICA OTHERS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 99
TABLE 42 NORTH AMERICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 103
TABLE 43 NORTH AMERICA INJECTABLE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 104
TABLE 44 NORTH AMERICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 104
TABLE 45 NORTH AMERICA ORAL IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 105
TABLE 46 NORTH AMERICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 109
TABLE 47 NORTH AMERICA MALE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 110
TABLE 48 NORTH AMERICA FEMALE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 110
TABLE 49 NORTH AMERICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 114
TABLE 50 NORTH AMERICA ADULT IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 115
TABLE 51 NORTH AMERICA PEDIATRIC IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 115
TABLE 52 NORTH AMERICA GERIATRIC IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 116
TABLE 53 NORTH AMERICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 120
TABLE 54 NORTH AMERICA 20-50 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 121
TABLE 55 NORTH AMERICA LESS THAN 20 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 122
TABLE 56 NORTH AMERICA ABOVE 50 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 123
TABLE 57 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 127
TABLE 58 NORTH AMERICA B2B IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 128
TABLE 59 NORTH AMERICA B2C IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 128
TABLE 60 NORTH AMERICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND) 132
TABLE 61 NORTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 132
TABLE 62 NORTH AMERICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 133
TABLE 63 NORTH AMERICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 133
TABLE 64 NORTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 134
TABLE 65 NORTH AMERICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 134
TABLE 66 NORTH AMERICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 135
TABLE 67 NORTH AMERICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 135
TABLE 68 NORTH AMERICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 135
TABLE 69 NORTH AMERICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 136
TABLE 70 NORTH AMERICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 136
TABLE 71 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 137
TABLE 72 NORTH AMERICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 138
TABLE 73 NORTH AMERICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 138
TABLE 74 NORTH AMERICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 138
TABLE 75 NORTH AMERICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 139
TABLE 76 NORTH AMERICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 139
TABLE 77 NORTH AMERICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 139
TABLE 78 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 139
TABLE 79 U.S. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 140
TABLE 80 U.S. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 140
TABLE 81 U.S. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 141
TABLE 82 U.S. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 141
TABLE 83 U.S. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 142
TABLE 84 U.S. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 142
TABLE 85 U.S. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 142
TABLE 86 U.S. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 143
TABLE 87 U.S. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 143
TABLE 88 U.S. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 144
TABLE 89 U.S. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 144
TABLE 90 U.S. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 145
TABLE 91 U.S. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 145
TABLE 92 U.S. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 145
TABLE 93 U.S. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 145
TABLE 94 U.S. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 146
TABLE 95 U.S. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 146
TABLE 96 U.S. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 146
TABLE 97 CANADA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 147
TABLE 98 CANADA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 147
TABLE 99 CANADA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 148
TABLE 100 CANADA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 148
TABLE 101 CANADA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 149
TABLE 102 CANADA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 149
TABLE 103 CANADA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 149
TABLE 104 CANADA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 150
TABLE 105 CANADA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 151
TABLE 106 CANADA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 151
TABLE 107 CANADA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 152
TABLE 108 CANADA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 152
TABLE 109 CANADA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 153
TABLE 110 CANADA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 153
TABLE 111 CANADA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 153
TABLE 112 CANADA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 154
TABLE 113 CANADA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 154
TABLE 114 CANADA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 154
TABLE 115 MEXICO TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 155
TABLE 116 MEXICO TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 155
TABLE 117 MEXICO INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 156
TABLE 118 MEXICO SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 156
TABLE 119 MEXICO LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 157
TABLE 120 MEXICO TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 157
TABLE 121 MEXICO TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 157
TABLE 122 MEXICO RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 158
TABLE 123 MEXICO ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 158
TABLE 124 MEXICO REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 159
TABLE 125 MEXICO TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 159
TABLE 126 MEXICO HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 160
TABLE 127 MEXICO TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 160
TABLE 128 MEXICO INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 160
TABLE 129 MEXICO TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 161
TABLE 130 MEXICO TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 161
TABLE 131 MEXICO TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 161
TABLE 132 MEXICO TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 161

LIST OF FIGURES

FIGURE 1 NORTH AMERICA TRAVEL VACCINES MARKET: SEGMENTATION 24
FIGURE 2 NORTH AMERICA TRAVEL VACCINES MARKET: DATA TRIANGULATION 27
FIGURE 3 NORTH AMERICA TRAVEL VACCINES MARKET: DROC ANALYSIS 28
FIGURE 4 NORTH AMERICA TRAVEL VACCINES MARKET : NORTH AMERICA VS REGIONAL MARKET ANALYSIS 29
FIGURE 5 NORTH AMERICA TRAVEL VACCINES MARKET : COMPANY RESEARCH ANALYSIS 29
FIGURE 6 NORTH AMERICA TRAVEL VACCINES MARKET: INTERVIEW DEMOGRAPHICS 31
FIGURE 7 NORTH AMERICA TRAVEL VACCINES MARKET: DBMR MARKET POSITION GRID 32
FIGURE 8 NORTH AMERICA TRAVEL VACCINES MARKET: MARKET APPLICATION COVERAGE GRID 33
FIGURE 9 NORTH AMERICA TRAVEL VACCINES MARKET: VENDOR SHARE ANALYSIS 34
FIGURE 10 NORTH AMERICA TRAVEL VACCINES MARKET: SEGMENTATION 38
FIGURE 11 RISING AWARENESS ABOUT THE IMPORTANCE OF VACCINATION AMONG TRAVELERS ARE EXPECTED TO DRIVE THE NORTH AMERICA TRAVEL VACCINES MARKET IN THE FORECAST PERIOD OF 2024 TO 2032 39
FIGURE 12 COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TRAVEL VACCINES MARKET IN 2021 & 2032 39
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA TRAVEL VACCINE MARKET 47
FIGURE 14 NORTH AMERICA TRAVEL VACCINE MARKET: BY COMPOSITION, 2023 58
FIGURE 15 NORTH AMERICA TRAVEL VACCINE MARKET: BY COMPOSITION, 2024-2032 (USD THOUSAND) 59
FIGURE 16 NORTH AMERICA TRAVEL VACCINE MARKET: BY COMPOSITION , CAGR (2024-2032) 59
FIGURE 17 NORTH AMERICA TRAVEL VACCINE MARKET: BY COMPOSITION, LIFELINE CURVE 60
FIGURE 18 NORTH AMERICA TRAVEL VACCINE MARKET: BY TYPE, 2023 63
FIGURE 19 NORTH AMERICA TRAVEL VACCINE MARKET: BY TYPE, 2024-2032 (USD THOUSAND) 64
FIGURE 20 NORTH AMERICA TRAVEL VACCINE MARKET: BY TYPE, CAGR (2024-2032) 64
FIGURE 21 NORTH AMERICA TRAVEL VACCINE MARKET: BY TYPE, LIFELINE CURVE 65
FIGURE 22 NORTH AMERICA TRAVEL VACCINE MARKET: BY CATEGORY, 2023 76
FIGURE 23 NORTH AMERICA TRAVEL VACCINE MARKET: BY CATEGORY, 2024-2032 (USD THOUSAND) 77
FIGURE 24 NORTH AMERICA TRAVEL VACCINE MARKET: BY CATEGORY, CAGR (2024-2032) 77
FIGURE 25 NORTH AMERICA TRAVEL VACCINE MARKET: BY CATEGORY, LIFELINE CURVE 78
FIGURE 26 NORTH AMERICA TRAVEL VACCINE MARKET: BY DISEASE, 2023 86
FIGURE 27 NORTH AMERICA TRAVEL VACCINE MARKET: BY DISEASE, 2024-2032 (USD THOUSAND) 87
FIGURE 28 NORTH AMERICA TRAVEL VACCINE MARKET: BY DISEASE, CAGR (2024-2032) 87
FIGURE 29 NORTH AMERICA TRAVEL VACCINE MARKET: BY DISEASE, LIFELINE CURVE 88
FIGURE 30 NORTH AMERICA TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, 2023 100
FIGURE 31 NORTH AMERICA TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2032 (USD THOUSAND) 101
FIGURE 32 NORTH AMERICA TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2032) 101
FIGURE 33 NORTH AMERICA TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 102
FIGURE 34 NORTH AMERICA TRAVEL VACCINE MARKET: BY GENDER, 2023 106
FIGURE 35 NORTH AMERICA TRAVEL VACCINE MARKET: BY GENDER, 2024-2032 (USD THOUSAND) 107
FIGURE 36 NORTH AMERICA TRAVEL VACCINE MARKET: BY GENDER, CAGR (2024-2032) 107
FIGURE 37 NORTH AMERICA TRAVEL VACCINE MARKET: BY GENDER, LIFELINE CURVE 108
FIGURE 38 NORTH AMERICA TRAVEL VACCINE MARKET: BY PATIENT TYPE, 2023 111
FIGURE 39 NORTH AMERICA TRAVEL VACCINE MARKET: BY PATIENT TYPE, 2024-2032 (USD THOUSAND) 112
FIGURE 40 NORTH AMERICA TRAVEL VACCINE MARKET: BY PATIENT TYPE, CAGR (2024-2032) 112
FIGURE 41 NORTH AMERICA TRAVEL VACCINE MARKET: BY PATIENT TYPE, LIFELINE CURVE 113
FIGURE 42 NORTH AMERICA TRAVEL VACCINE MARKET: BY AGE GROUP, 2023 117
FIGURE 43 NORTH AMERICA TRAVEL VACCINE MARKET: BY AGE GROUP, 2024-2032 (USD THOUSAND) 118
FIGURE 44 NORTH AMERICA TRAVEL VACCINE MARKET: BY AGE GROUP, CAGR (2024-2032) 118
FIGURE 45 NORTH AMERICA TRAVEL VACCINE MARKET: BY AGE GROUP, LIFELINE CURVE 119
FIGURE 46 NORTH AMERICA TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, 2023 124
FIGURE 47 NORTH AMERICA TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, 2024-2032 (USD THOUSAND) 125
FIGURE 48 NORTH AMERICA TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2032) 125
FIGURE 49 NORTH AMERICA TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 126
FIGURE 50 NORTH AMERICA TRAVEL VACCINE MARKET: SNAPSHOT (2023) 129
FIGURE 51 NORTH AMERICA TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%) 161